PDL BioPharma Appoints Peter Garcia as Chief Financial Officer

        PDL BioPharma Appoints Peter Garcia as Chief Financial Officer

PR Newswire

INCLINE VILLAGE, Nev., April 30, 2013

INCLINE VILLAGE, Nev., April 30, 2013 /PRNewswire/ --PDL BioPharma, Inc.
(PDL) (NASDAQ: PDLI) today announced that the Company has appointed Peter S.
Garcia to the position of vice president, chief financial officer (CFO) and
acting chief accounting officer, effective as of May 13, 2013. Mr. Garcia has
spent the last 16 years in various CFO positions for biotechnology companies.
He joins PDL from BioTime, Inc. (NYSE MKT: BTX) where he served as CFO since

(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO )

"Peter is a welcome addition to our management team. His depth of experience
in managing financial reporting for public biotech companies as well as his
proven ability to negotiate and structure transactions will be invaluable to
PDL," stated John P. McLaughlin, president and chief executive officer of

"I am excited to join PDL at this point in the company's journey," stated Mr.
Garcia. "PDL has a leadership team that is committed to returning value to
its shareholders, both through dividend payments as well as through the
acquisition of income generating assets. Significant progress has been made
over the past year to generate additional income for PDL, and I look forward
to participating in continued value creation."

Peter S. Garcia most recently served as CFO of BioTime, Inc., which he joined
in 2011. Between the years of 1996 and 2011, Mr. Garcia was CFO of six biotech
and high-tech companies, including Marina Biotech, Nanosys, Nuvelo, Novacept,
IntraBiotics Pharmaceuticals and Dendreon Corporation. While at these
companies, he raised over $550 million, led multiple merger and acquisition
transactions, and managed multiple functions including finance, accounting,
treasury, investor relations, corporate communications, IT and facilities.
From 1990 to 1996, he was a finance executive with Amgen.Mr. Garcia holds a
B.A. in economics and sociology with honors from Stanford University and an
MBA with an emphasis in finance and accounting from UCLA.

About PDL BioPharma
PDL pioneered the humanization of monoclonal antibodies and, by doing so,
enabled the discovery of a new generation of targeted treatments for cancer
and immunologic diseases. Today, PDL is focused on intellectual property asset
management, investing in new income generating assets and maximizing value for
its shareholders. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of
PDL BioPharma, Inc.

Forward-looking Statements
This press release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Each of these forward-looking
statements involves risks and uncertainties. Actual results may differ
materially from those, express or implied, in these forward-looking
statements. Important factors that could impair the Company's business are
disclosed in the risk factors contained in the Company's 2012 Annual Report on
Form 10-K filed with the Securities and Exchange Commission. All
forward-looking statements are expressly qualified in their entirety by such
factors. We do not undertake any duty to update any forward-looking statement
except as required by law.

SOURCE PDL BioPharma, Inc.

Website: http://www.pdl.com
Contact: John McLaughlin, PDL BioPharma, Inc., 775-832-8500,
john.mclaughlin@pdl.com; Jennifer Williams, Cook Williams Communications,
Inc., 360-668-3701, jennifer@cwcomm.org
Press spacebar to pause and continue. Press esc to stop.